Australia’s R&D Tax Cap Creates a Biotech Funding Cliff

A ten-year cap on cash refunds sounds administratively tidy until it is mapped against a twelve-to-fifteen-year commercialisation timeline. The mismatch is not theoretical; it describes the actual development arc of the sectors most affected. Australia’s proposed changes to the Research and Development Tax Incentive (RDTI), announced in the 2026-27 Federal Budget, would restrict the refundable cash component of R&D tax offsets to a company’s first 10 years of operation. The reforms are not yet law. Draft legislation is expected in 2027, with commencement scheduled for 1 July 2028, and the Senate Economics Legislation Committee is currently reviewing submissions. What follows is an analysis of why the R&D tax cap in Australia creates a structurally different category of risk for long-cycle sectors, how that risk translates into specific portfolio and valuation considerations, and what the current Senate submissions are asking the Government to address.

What the 10-year R&D refundability cap actually does

The RDTI programme itself is not being abolished or capped. The change targets a single mechanism: the cash refund. Under the proposed reform, refundable R&D tax offsets would be restricted to companies in their first 10 years of operation. After that threshold, companies continue to receive a tax offset, but only on a non-refundable basis, meaning the credit is carried forward and only realises value against future taxable income.

The ATO guidance on RDTI reforms confirms seven distinct changes to the programme taking effect from 1 July 2028, with the restriction of refundable offset access to a company’s first 10 years of operation sitting alongside the revised turnover threshold and expenditure cap adjustments.

For pre-revenue companies, the distinction is the difference between a functioning cash runway and a ledger entry. A non-refundable credit has real value for an ultimately profitable company. For a firm burning cash through late-stage clinical trials or hardware scale-up with no revenue in sight, it offers no cashflow relief whatsoever.

Recce Pharmaceuticals illustrates the mechanics in practice: a non-dilutive R&D rebate of $5.3 million at the current 43.5% rate funded the company’s Phase 3 anti-infective trial without shareholder dilution, extending the runway through a critical late-stage development window that falls precisely in the years the proposed cap would affect most.

The thresholds and rates that change alongside the cap

Several numerical parameters shift under the proposed structure:

• Refundable offset turnover threshold rises from $20 million to $50 million
• Maximum eligible R&D expenditure increases from $150 million to $200 million per year
• Minimum annual R&D spend rises from $20,000 to $50,000 (unless via an approved research service provider)
• The refundable offset rate increases to approximately 23 percentage points above the company tax rate, equating to roughly a 48% cash rebate (up from 43.5%)
• Supporting R&D activities (administration, literature reviews, maintenance) will no longer be eligible; only core experimental R&D qualifies

Younger firms with clearly demonstrable experimental activity may benefit from the higher rates, even as older firms lose refundability entirely.

Why deep tech and medtech face a structurally different problem

The arithmetic makes the sector mismatch visible before any editorial framing is required. Complex clinical therapies and advanced hardware products typically require 12 to 15-plus years from discovery to commercial viability, a timeline encompassing preclinical work, Phase I through III clinical trials, and regulatory approval. The most resource-intensive phases, late-stage trials and pre-commercialisation scale-up, fall precisely outside the 10-year support window.

Software and SaaS companies commonly complete core product development in three to five years. They are more likely to reach profitability within a timeframe where the transition from refundable to non-refundable credit is manageable. The policy does not affect these sectors uniformly; it creates two distinct risk profiles from the same legislative change.

Policy commentary submitted to the Senate warns that the cap “misunderstands the long commercialisation timelines behind biotechnology and medical technology.”

The gap between development timeline and support window is not marginal for biotech and medtech. It covers precisely the period when burn rates remain highest and revenue may still be years away.

How Australia’s R&D support compares once refundability disappears

Once the cash stops arriving, the question for a globally mobile founder becomes practical: what does Australia’s offering look like on a spreadsheet next to peer jurisdictions? Several countries provide refundable or super-deduction-style incentives and have been actively tuning them to attract IP-intensive activities:

• United Kingdom: Enhanced R&D tax relief with refundable credit for loss-making R&D-intensive companies
• Canada: Refundable Scientific Research and Experimental Development (SR&ED) credits
• Singapore: Concessional IP and R&D incentive regimes targeting life sciences
• Israel: Innovation Authority grants with equity-free support mechanisms
• United States: Federal R&D tax credit with state-level supplementary programmes

Australia’s reform is explicitly designed to moderate fiscal cost growth rather than compete on generosity. The practical consequence is that the shift from refundable to non-refundable support increases reliance on external equity and venture capital during the pre-revenue phase, making Australian after-tax cashflow comparatively less attractive.

Australia’s innovation funding gap extends well beyond the RDTI: Australian startups raised approximately $5.4 billion in 2025 but 66% of those deals required at least one offshore investor, a structural reliance on foreign capital that tightens further when domestic incentive settings deteriorate relative to peer markets.

The founder mobility problem

For globally mobile founders, the reform creates a real option to shift future R&D steps or holding company domicile to jurisdictions with more favourable refundable incentive structures. This is not a theoretical concern for policy commentators; it is a capital retention risk for the Australian innovation pipeline. If after-tax cashflows deteriorate relative to peer markets during the commercialisation window, the incentive to incorporate or relocate research activity offshore becomes a portfolio-level variable for investors holding Australian deep tech and medtech.

Reading the 89% investor sentiment figure and what it signals

According to a formal Senate submission by Wholesale Investor and CapitalHQ (June 2026), 89% of investors surveyed reported significantly reduced appetite for funding deep tech, medtech, and life sciences sectors if the proposed 10-year cap is enacted.

The figure demands appropriate interpretive weight. Several methodological caveats apply:

• The data originates from an internal investor survey conducted for the Senate submission, not from publicly available government or industry-wide statistics
• Methodology details, including investor type, sample size, and collection period, have not been publicly disclosed
• No independent corroboration of the figure has been cited
• The unusually high percentage makes this the most contestable data point in the reform debate

If investor intent tracks this direction even partially, the effect on capital availability for pre-revenue deep tech and medtech companies would be material. Senate submission sentiment surveys carry less weight than market-wide data. In a thinly traded, illiquid asset class like early-stage deep tech, however, a documented directional shift in wholesale investor appetite is a risk signal that warrants monitoring rather than dismissal.

Four investor risk dimensions that need to be modelled now

The reform is not yet law, but the 1 July 2028 commencement date means companies already past year five or six of operation are approaching the refundability cliff within a single investment horizon. Four distinct portfolio-level variables warrant stress-testing:

1. Duration matching: The 10-year clock runs from the company’s incorporation date or first R&D claim year. Investors in companies approaching year 7 to 10 should model the refundability cliff explicitly into cash runway projections. The transition from cash to non-cash support is binary, not gradual.
2. Capital requirement reassessment: Removing the refundable component can materially increase required equity capital and expected dilution in late development stages. Lost annual cash refunds must be replaced by additional equity raises at a point when the company’s risk profile remains high and market conditions uncertain.
3. Valuation and exit sensitivity: For secondary buyers or acquirers, a looming refundability cliff may be priced into valuations. Portfolio companies approaching or past the 10-year mark with pre-revenue status may face downward valuation pressure from buyers who model the cashflow impact of losing refundability.
4. Comparative jurisdiction attractiveness: For globally mobile portfolio companies, the reform creates a real incentive to evaluate future R&D steps or holding company domicile in jurisdictions with more favourable refundable incentive structures. Where a company chooses to be incorporated by the time it reaches commercialisation may shift.

These risk dimensions are not hypothetical for investors currently deploying capital into Australian innovation assets. They are modellable variables with a defined legislative timeline.

What the Senate submission proposes to fix and why it matters

The specific asks in the Wholesale Investor and CapitalHQ Senate submission reveal which structural failures the innovation sector considers most consequential. The submission acknowledges broad ecosystem support for housing-related tax reform while seeking to insulate productive enterprise investment from collateral damage.

The RDTI reform sits within a broader tax reform package that includes the replacement of the 50% CGT discount with cost-base indexation and a 30% minimum tax from 1 July 2027, and modelling of the CGT changes shows how the flat-discount architecture created structural distortions that a tapered alternative would have addressed without concentrating the burden on long-cycle productive investment.

Five specific recommendations were put forward:

• Limit the removal of the 50% CGT discount and the 30% minimum tax floor specifically to residential property, leaving innovation equity settings unchanged
• Extend concessional CGT treatment to individual angel investors, private syndicates, and Employee Share Ownership Plan (ESOP) holders
• Accommodate irregular, infrequent capital realisation events under the minimum tax floor
• Either exempt or substantially extend the 10-year refundable R&D cap for sectors with demonstrably long development cycles, specifically naming biotech and advanced manufacturing
• Preserve the structural distinction between housing speculation and productive enterprise investment

Investors do not need to be passive observers of this reform debate. Tracking whether the sector exemptions for biotech and advanced manufacturing survive the legislative process is directly relevant to portfolio positioning.

The funding cliff is structural, not incidental, and the window to shape it is now

The 10-year refundability cap is not a marginal adjustment. It creates a policy-driven funding cliff at precisely the commercialisation phase where capital requirements are highest for long-cycle sectors. Fast-cycle sectors can adapt; deep tech, medtech, and life sciences face a structural mismatch between the support window and their actual development timelines.

The reform is not yet law. The Senate consultation window remains open as of June 2026, and the 1 July 2028 commencement date creates a defined horizon for portfolio review. The specific asks in the Senate submissions, particularly sector exemptions for biotech and advanced manufacturing, represent the clearest indicator of what a reformed version of this policy could look like. Whether those exemptions survive the legislative process is the single most important variable for investors with exposure to Australian innovation assets.

For investors wanting a framework to weight legislative risk before the draft legislation arrives in 2027, our dedicated guide to reading tax policy signals examines three May 2026 case studies, including Australia’s CGT reform, to show how enactment probability, implementation lag, and legislative stage combine to determine when a policy announcement becomes a portfolio-level signal rather than market noise.

This article is for informational purposes only and should not be considered financial advice. Investors should conduct their own research and consult with financial professionals before making investment decisions. These statements are speculative and subject to change based on market developments and legislative outcomes.